About caplacizumab
Anti-von Willebrand factor antibody fragment
Used for
- Treats acquired thrombotic thrombocytopenic purpura (aTTP), alongside plasma exchange and immunosuppressive treatment.
Usual adult dose
11 mg by intravenous injection before plasma exchange, then 11 mg under the skin after exchange; continue daily during plasma exchange and for 30 days afterward. Treatment may be extended by a clinician.
Common side effects
- Nosebleeds or other bleeding
- Headache
- Gum bleeding
- Injection-site reactions
Important warnings
- Increases bleeding risk; serious or fatal bleeding can occur.
- Use caution with anticoagulants, antiplatelet medicines, or bleeding disorders.
- Tell clinicians before surgery or dental procedures; treatment may need interruption.
- Monitor for allergic reactions, including swelling or breathing difficulty.
Pregnancy
Human pregnancy information is limited. Use only when the expected benefit outweighs potential risk.
Breastfeeding
It is not known whether caplacizumab passes into breast milk. Consider treatment benefits and breastfeeding needs with a clinician.
Interactions
- Anticoagulants and antiplatelet medicines may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.